2 results
Approved WMOWill not start
Primary Objectives* To assess the safety and tolerability of Foxy-5 in subjects with colon cancer.* To assess circulating tumour DNA (ctDNA) in plasma as a surrogate parameter for disease recurrences in subjects with Wnt-5a low colon cancer treated…
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…